Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESAT6-CFP10 Skin Test Specificity and Safety in Healthy Adults
NCT02795260Phase 3Completed
- Sponsor
- Zhifei Biological
- Start
- May 2016
- Primary completion
- Oct 2016
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
01
Overview
Phase 3, randomised, double-blind trial of C-Tb in Tuberculosis (TB) (2 arms), sponsored by Zhifei Biological. Primary endpoints: Number of study population III Negative for Reaction at 24 hours After intradermal injection with EC or TB-PPD and Number of study population III Negative for Reaction at 48 hours After intradermal injection with EC or TB-PPD. Started May 2016; status: completed.
02
Drugs
C-Tb
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT02795260.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02795260.